4.8 Article

Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors

Journal

NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-01657-3

Keywords

-

Funding

  1. AbbVie [1097737]
  2. Bayer Pharma AG [1097737]
  3. Boehringer Ingelheim [1097737]
  4. Canada Foundation for Innovation [1097737]
  5. Eshelman Institute for Innovation [1097737]
  6. Genome Canada through Ontario Genomics Institute [1097737, OGI-055]
  7. Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD) [1097737, 115766]
  8. Janssen [1097737]
  9. Merck Co. [1097737]
  10. Novartis Pharma AG [1097737]
  11. Ontario Ministry of Research, Innovation and Science (MRIS) [1097737]
  12. Pfizer [1097737]
  13. Sao Paulo Research Foundation-FAPESP [1097737]
  14. Takeda [1097737]
  15. Wellcome Trust [1097737]

Ask authors/readers for more resources

Many compounds with potentially reactive chemical motifs and poor physicochemical properties are published as selective modulators of biomolecules without sufficient validation and then propagated in the scientific literature as useful chemical probes. Several histone acetyltransferase (HAT) inhibitors with these liabilities are now routinely used to probe epigenetic pathways. We profile the most commonly used HAT inhibitors and confirm that the majority of them are nonselective interference compounds. Most (15 out of 23, 65%) of the inhibitors are flagged by ALARM NMR, an industry-developed counter-screen for promiscuous compounds. Biochemical counter-screens confirm that most of these compounds are either thiol-reactive or aggregators. Selectivity panels show many of these compounds modulate unrelated targets in vitro, while several also demonstrate nonspecific effects in cell assays. These data demonstrate the usefulness of performing counter-screens for bioassay promiscuity and assay interference, and raise caution about the utility of many widely used, but insufficiently validated, compounds employed in chemical biology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available